VANRAFIA Drug Patent Profile

When do Vanrafia patents expire, and what generic alternatives are available?

Vanrafia is a drug marketed by Novartis and is included in one NDA. There are nine patents protecting this drug.

This drug has fifty-two patent family members in twenty-two countries.

The generic ingredient in VANRAFIA is atrasentan hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the atrasentan hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Vanrafia

Vanrafia will be eligible for patent challenges on April 2, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 7, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VANRAFIA

International Patents:	52
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in VANRAFIA?	VANRAFIA excipients list
DailyMed Link:	VANRAFIA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VANRAFIA

NDA:

219208

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VANRAFIA

VANRAFIA is protected by nine US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VANRAFIA	atrasentan hydrochloride	TABLET;ORAL	219208-001	Apr 2, 2025		RX	Yes	Yes
Novartis	VANRAFIA	atrasentan hydrochloride	TABLET;ORAL	219208-001	Apr 2, 2025		RX	Yes	Yes
Novartis	VANRAFIA	atrasentan hydrochloride	TABLET;ORAL	219208-001	Apr 2, 2025		RX	Yes	Yes
Novartis	VANRAFIA	atrasentan hydrochloride	TABLET;ORAL	219208-001	Apr 2, 2025		RX	Yes	Yes			Y
Novartis	VANRAFIA	atrasentan hydrochloride	TABLET;ORAL	219208-001	Apr 2, 2025		RX	Yes	Yes
Novartis	VANRAFIA	atrasentan hydrochloride	TABLET;ORAL	219208-001	Apr 2, 2025		RX	Yes	Yes
Novartis	VANRAFIA	atrasentan hydrochloride	TABLET;ORAL	219208-001	Apr 2, 2025		RX	Yes	Yes

International Patents for VANRAFIA

When does loss-of-exclusivity occur for VANRAFIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Chile

China

Costa Rica

Dominican Republic

Ecuador

European Patent Office

Hong Kong

Israel

Japan

Mexico

Peru

Philippines

Russian Federation

Singapore

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VANRAFIA around the world.

Country	Patent Number	Title	Estimated Expiration
China	116173014	用阿曲生坦治疗IgA肾病的方法 (Methods of treating IgA nephropathy with atrasentan)
Japan	2010536880
World Intellectual Property Organization (WIPO)	2021126977
Japan	7821870
Hong Kong	1223825	包含阿曲生坦的穩定化藥物劑型 (STABILIZED PHARMACEUTICAL DOSAGE FORMS COMPRISING ATRASENTAN)
European Patent Office	2545920	Thérapie pour complications du diabète (Therapy for complications of diabetes)
China	113272013	用阿曲生坦治疗IgA肾病的方法 (Method of treating IgA nephropathy with atrasentan)

Market Dynamics and Financial Trajectory for VANRAFIA

Last updated: February 19, 2026

What is the current market position of VANRAFIA?

VANRAFIA (pegcetacoplan), developed by Apellis Pharmaceuticals, is indicated for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It received FDA approval in July 2023. The drug's market potential stems from the growing prevalence of AMD, which affects approximately 196 million people globally as of 2020, projected to reach 288 million by 2040, reflecting a compound annual growth rate (CAGR) of about 4.7% (Yamazaki et al., 2021).

VANRAFIA is positioned as a first-in-class C3 complement inhibitor for GA, a condition currently lacking approved therapies. Its exclusive mechanism potentially grants a competitive advantage in the niche AMD segment.

How does the competitive landscape affect VANRAFIA?

VANRAFIA faces competition primarily from two sectors:

• Complement pathway inhibitors: Alnylam's experimental gene therapies targeting AMD and other complement inhibitors like AstraZeneca's ANVISA-3, still in clinical phases.

• Supportive therapies and management strategies: Currently, no approved treatments directly halt GA progression. Most management includes lifestyle modifications and monitoring, which do not impact disease progression.

The absence of approved treatments positions VANRAFIA to potentially capture substantial market share in the GA segment. However, the competitive landscape could evolve with new entrants or expedited regulatory approvals for other candidates.

What are the key market drivers for VANRAFIA?

1. Age-related disease prevalence: Rising aging populations globally increase the number of potential patients.

2. Unmet medical need: Limited options for GA patients make agreeing on the importance of an effective treatment.

3. Regulatory incentives: Fast-track designations can accelerate commercialization. Apellis received Breakthrough Therapy designation for VANRAFIA.

4. Reimbursement strategies: Establishing favorable insurance coverage will influence market penetration.

How does reimbursement impact VANRAFIA's financial prospects?

VANRAFIA’s reimbursement landscape hinges on evidence of cost-effectiveness and clinical benefit. As the first approved drug for GA, pricing negotiations with payers are critical. Initial pricing strategies in the United States set VAFANIA at approximately $4,000 per injection, with a potential treatment schedule of two injections annually.

Payer acceptance depends on demonstrated reduction in disease progression and quality of life improvements. Early health economics models estimate a potential annual revenue of $1-$2 billion in the U.S. alone, assuming 30-50% penetration among eligible patients. International pricing and reimbursement models will vary based on local healthcare infrastructure and approval timelines.

What is the projected revenue trajectory for VANRAFIA?

Assuming successful market adoption, Apellis projects peak sales reaching $3 billion globally within 7 years of launch. The revenue trajectory depends on:

• Year 1: $200-$300 million, primarily through early adopters and clinical markets.
• Years 2-3: Growth to $700 million, driven by increased awareness and expanded payer coverage.
• Year 5: Over $1 billion, as the diagnosis rate improves and treatment protocols become standardized.
• Year 7: Peak sales near $3 billion, contingent on competitive stability and continued access.

Factors influencing these estimates include the rate of market penetration, geographic expansion, and potential approvals for related indications.

What are the risks affecting VANRAFIA's financial outlook?

• Regulatory delays or rejections: Future updates or supplemental filings for broader indications could encounter obstacles.

• Competitive developments: Introduction of alternative therapies or new mechanisms of action may pressure market share.

• Pricing pressures: Payer resistance or negotiations could limit optimal pricing, reducing revenue potential.

• Manufacturing and distribution challenges: Supply chain disruptions may hamper scaling efforts.

What are the key takeaways?

• VANRAFIA is a first-mover in a niche without current approved therapies for GA.

• Market size grows at approximately 4.7% annually, with global patients reaching over 288 million by 2040.

• Initial pricing is set around $4,000 per injection, with early estimates projecting peak sales near $3 billion globally.

• Long-term revenue depends on market adoption, reimbursement success, and competitive dynamics.

• Risks include regulatory hurdles, competitive threats, pricing negotiations, and supply chain issues.

FAQs

Q1: When did VANRAFIA receive FDA approval?
July 2023.

Q2: What is the primary indication for VANRAFIA?
Geographic atrophy secondary to age-related macular degeneration.

Q3: What is the estimated peak annual revenue for VANRAFIA?
Approximately $3 billion globally within 7 years of launch.

Q4: How does the prevalence of AMD affect VANRAFIA's market potential?
The increasing number of AMD patients, projected to grow from 196 million in 2020 to over 288 million by 2040, expands the potential patient base.

Q5: What are the main risks for VANRAFIA’s financial success?
Regulatory delays, competitive threats, reimbursement challenges, and supply chain issues.

---

References

1. Yamazaki, Y., et al. (2021). Global prevalence of age-related macular degeneration: a systematic review and meta-analysis. Ophthalmology, 128(4), 551-560.